Validación del método analítico para la determinación de glimepirida en plasma humano por HPLC/UV con adición de estándar empleando glibenclamida como estándar interno

Ars Pharmaceutica 01/2005; 46(4).
Source: OAI

ABSTRACT Se desarrolló un método para la detección y cuantificación de Glimepirida en plasma humano, con elución isocrática por cromatografía líquida de fase reversa, con detección ultravioleta a 231 nm, empleando el método de adición de estándar. Se utilizó Glibenclamida como estándar interno. Este método involucra una extracción líquida de los principios activos (Glimepirida y Glibenclamida) usando una mezcla de diclorometano:dietiléter (30:70 v/v). La separación se realizó en una columna C 18 en fase reversa y la fase móvil consistió de una mezcla de acetonitrilo:agua (45:55 v/v) ajustado a pH 3.3±0.1 con ácido acético glacial. El método se validó en el rango de concentraciones de 0.001 a 1.0 µg/mL con adición de estándar de Glimepirida de 0.25 µg/mL. La curva de calibración fue lineal en el rango de concentraciones establecido. Se evaluó la reproducibilidad, estabilidad y porcentaje de recuperación del método. El método para la determinación de Glimepirida en plasma humano por HPLC/UV fue preciso y exacto, con un límite de cuantificación de 0.2025 µg/mL. Este método fue suficientemente sensible para su aplicación en estudios farmacocinéticos de glimepirida.

18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A sensitive and specific high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (HPLC-ESI-MS-MS) method has been developed at our center for the determination of glimepiride in human plasma. After the addition of the internal standard, plasma samples were extracted by liquid-liquid extraction technique using diethyl ether. The compounds were separated on a prepacked C18 column using a mixture of acetonitrile, methanol and ammonium acetate buffer as mobile phase. A Finnigan LCQDUO ion trap mass spectrometer connected to an Alliance Waters HPLC was used to develop and validate the method. The analytical method was validated according to the FDA bioanalytical method validation guidance. The results were within the accepted criteria as stated in the aforementioned guidance. The method was proved to be sensitive and specific by testing six different plasma batches. Linearity was established for the range of concentrations 5.0-500.0 ng/ml with a coefficient of determination (r2) of 0.9998. Accuracy for glimepiride ranged from 100.58 to 104.48% at low, mid and high levels. The intra-day precision was better than 12.24%. The lower limit of quantitation (LLOQ) was identifiable and reproducible at 5.0 ng/ml with a precision of 7.96%. The proposed method enables the unambiguous identification and quantitation of glimepiride for pharmacokinetic, bioavailability or bioequivalence studies.
    Journal of Chromatography B 02/2004; 799(1):103-9. DOI:10.1016/j.jchromb.2003.10.024 · 2.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A sensitive high-performance liquid chromatographic method for determination of intact glibenclamide in human plasma has been developed. Sample clean-up prior to chromatographic analysis was accomplished by extraction of the drug using a solid-phase RP-8 or RP-18 cartridge instead of the conventional liquid-liquid extraction methods described. For the separation of the drug from the endogenous components a reversed-phase column (LiChrosorb RP-8) of 5 microns particle size and 250 x 4 mm I.D., together with a mobile phase consisting of aceronitrile-12 mM perchloric acid (47:53) was selected. The method employs progesterone as an internal standard, and a reversed-phase column combined with UV detection of the drug at 230 nm. The detector response was linear up to the concentration of 400 ng/ml and the average recovery was 100.36%. The sensitivity of the method was 5 ng/ml.
    Journal of chromatography. B, Biomedical applications 08/1996; 682(2):364-70. DOI:10.1016/0378-4347(95)00551-X
  • Diabetes 02/1970; 19(Suppl 1):Suppl:789-830. · 8.10 Impact Factor


18 Reads
Available from